
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is a leading life science technology company with a comprehensive suite of solutions for analyzing biological systems at a high resolution and scale, positioning them well in the growing biotechnology industry. With a strong geographically diversified revenue stream and a promising pipeline of new products including the recently acquired Visium and Xenium platforms, the company is poised for continued growth. In addition, aggressive moves such as the acquisition of Prime Mining signal a commitment to expanding their portfolio and solidifying their position as a leader in the market.
Bears say
10x Genomics is facing potential headwinds as the company continues to repurchase shares and pay dividends, potentially limiting their ability to invest in new growth opportunities. Additionally, their current valuation multiples are lower than their peers, suggesting that the market has a negative outlook on the company's future growth potential. This may be due to concerns over the company's dependence on one product line and limited diversification in their revenue streams. Furthermore, their valuation and NAVPS ratios indicate that the stock is currently undervalued, possibly due to investors' lack of confidence in the company's long-term prospects.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares